Background Activating RAS mutations in the germline cause rare developmental disorders such as Costello syndrome. Somatic RAS mutations are found in approximately 30% of human cancers. Keratinocytic epidermal nevi (KEN) represent benign congenital skin lesions arranged along Blaschko's lines. A subgroup of KEN is caused by hotspot oncogenic FGFR3 and PIK3CA mutations in mosaicism, but the majority lack these mutations. Methods This study screened 72 KEN for activating mutations in RAS genes and other oncogenes. Results Activating RAS mutations were identified in 28/72 (39%) of KEN. HRAS was the most commonly affected oncogene (86%), with the HRAS p.G13R substitution representing a new hotspot mutation. Conclusion These results indicate that activating RAS somatic mutations leading to mosaicism result in benign KEN of the skin. Given the prevalence of KEN, mosaic HRAS mutations appear to be more common in patients than germline ones. These findings identify KEN as a mosaic RASopathy and lend further support to the notion that genetic mosaicism is an important contributor to disease.
INTRODUCTION
Ras proteins regulate cell proliferation, survival, and differentiation. Somatic RAS mutations resulting in constitutive active proteins occur in 30% of human tumours; progression models assume that these mutations occur in the adult. 1 Activating germline RAS mutations have been identified in rare developmental disorders, such as HRAS mutations in Costello syndrome (CS), characterised by prenatal overgrowth and postnatal growth restriction, coarse face, skin alterations, cardiomyopathy, and cancer predisposition. 2 3 CS overlaps with Noonan and cardio-facio-cutaneous syndromes, caused by activating mutations in other genes of the RASeRAFeMAPK pathway. Non-organoid keratinocytic epidermal nevi (KEN) are benign congenital lesions displaying a linear distribution and resulting from genetic mosaicism; approximately 40% of KEN harbour postzygotic activating mutations in FGFR3 and PIK3CA genes. 7 8 However, the underlying gene mutation in the majority of KEN still remains unknown. In this study we show that approximately 40% of KEN are caused by postzygotic activating RAS mutations displaying a strong association between the genotype and the phenotype, with a predominance of the HRAS p.G13R mutation.
MATERIALS AND METHODS Sample acquisition
To identify novel genes causing KEN, we screened one lesion from each of 72 patients for hotspot mutations in various genes (table 1) . From one patient (no.27), three different biopsies of the KEN were available for analysis. The KEN were retrieved from the histopathological files of the contributing departments in Regensburg, Barcelona, and Friedrichshafen. The male:female ratio of the patients was 1:1.1, and the mean age at the time of the biopsy was 18.9613.1 years (table 1). The study was approved by the local ethics committees of the participating institutions and was performed according to the Declaration of Helsinki.
Mutation analyses
DNA was isolated from manually microdissected sections of formalin-fixed, paraffin-embedded tumours. FGFR3, PIK3CA, HRAS, NRAS, and KRAS mutations were analysed using SNaPshot assays (Applied Biosystems, Carlsbad, California, USA) as described previously.
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Each mutation was confirmed by a second independent PCR. Exon 4 of AKT1 harbouring the p.E17K hotspot mutation was sequenced directly as described previously. 11 Furthermore, direct sequencing (NRAS and HRAS) and pyrosequencing (KRAS) were performed in a subset of samples for validation of the mutations in independent laboratories. To screen for mutations in other oncogenes, the OncoCarta Panel v1.0 (Sequenom, San Diego, California, USA) covering mutations in ABL1, AKT1, AKT2, BRAF, CDK4,  EGFR, ERBB2, FGFR1, FGFR3, FLT3, HRAS, JAK2,  KIT, KRAS, MET, NRAS, PDGFRA, PIK3CA , and RET was used for a subset of 10 KEN being wildtype for the mutations mentioned above. 12 
RESULTS
Activating FGFR3 and PIK3CA mutations were found in 16/72 (22%) and in 6/72 (8%) KEN, respectively; hotspot oncogenic RAS mutations were identified in 28/72 (39%) of KEN ( figure 1A ; table 1). HRAS was the most frequently altered gene: in 21/24 HRAS-mutant lesions, the p.G13R (c.37G>C) substitution was found, thus representing a new hotspot mutation in KEN. In one patient, this mutation was found in three biopsies at different sites of the KEN. According to the COSMIC database (http://www.sanger.ac.uk/genetics/CGP/cosmic/), the p.G13R mutation is the most common HRAS mutation at codon 13 and has been described in tumours of the thyroid gland, upper aerodigestive tract, and urinary tract. The remaining three HRAS mutations (p.G12C, p.G12V, and p.Q61L) have also been previously described as somatic mutations in human tumours. Normal epidermis (n¼4) and dermis (n¼3) adjacent to the KEN, as well as blood DNA (n¼2), were available from some patients whose KEN had a HRAS p.G13R mutation. These normal tissues displayed a wild type HRAS sequence (figure 1B), indicating the somatic nature of the mutation and a strong association between its presence and the clinical phenotype of KEN. Three KEN harboured mutations in NRAS (p.G12D, p.P34L, and p. Q61R) and one in KRAS (p.G12D). AKT1 mutations were absent from 47 KEN analysed. In five KEN, two mutations were found simultaneously: HRAS (n¼3) or FGFR3 (n¼2) mutations cooccurred with PIK3CA mutations, but HRAS and FGFR3 mutations were mutually exclusive, as reported previously in cancers. 13 Similar mutational patterns are associated with seborrhoeic keratoses, benign epidermal tumours of the adult. 7 11 Overall, no mutation was identified in 27/72 (38%) KEN. To screen for further oncogenic mutations, 10 of these wildtype KEN were analysed using the OncoCarta Panel that covers 238 mutations in 19 oncogenes. 12 However, no additional mutations were identified using this technique.
DISCUSSION
Despite much research on RAS, there is still incomplete knowledge of the biological effects resulting from distinct RAS gene mutations. In the last few years, the concept of 'RASopathy' has been applied to developmental syndromes caused by germline mutations in genes of the RAS/MAPK pathway. 14 15 The RASopathies comprise CS, Noonan syndrome, LEOPARD syndrome (lentigines, ECG conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness), cardio-facio-cutaneous syndrome, neurofibromatosis type 1, hereditary gingival fibrosis, capillary malformationearteriovenous malformation syndrome, autoimmune proliferative syndrome, and Legius syndrome. The involvement of a common signalling pathway explains the phenotypical overlap between many of these disorders.
In this study we report that postzygotic RAS mutations affecting the epidermis can cause KEN. RAS genes therefore join FGFR3 and PIK3CA as oncogenes involved in benign congenital proliferative skin lesions. In KEN, HRAS was the most frequently mutated RAS gene. Germline HRAS mutations cause CS affecting a wide variety of tissues, including the skin, and involving both the epidermis and the dermis. Typical dermatological findings in CS patients comprise papillomas, palmoplantar keratoderma, deep palmar and plantar creases with loose and redundant skin, pachydermatoglyphia, abnormal fingernails, curly or wavy hair, generalised hyperpigmentation, hyperpigmented patches, and acanthosis nigricans. 16 The latter is also found in patients with FGFR3 germline mutations and shows histopathological similarities to KEN. Intriguingly, germline mutations of FGFR3 and HRAS are associated with acanthosis nigricans, whereas somatic postzygotic mutations of both genes in the skin result in KEN.
Mosaicism affecting RAS genes has been reported in a small number of subjects. Two patients with a CS phenotype harboured a p.G12S HRAS mosaicism, 17 suggesting an early occurrence of the mutation with extensive contribution to adult tissues. The sharply demarcated plaques and papules following Blaschko's lines are characteristic of KEN but have not been described in classical CS, indicating that HRAS mutant KEN are not simply incomplete manifestations of CS. Based on the clinical data available, none of the patients included in this study had typical features of CS or related disorders.
The mechanisms for the distinct phenotypes associated with germline versus postzygotic RAS mutations are unknown. Depending on the developmental stage and fate potential of the cells in which the mutations occur, different tissue compartments and cell types will be affected (eg, epidermis only versus both epidermis and dermis). Mosaicism implies the coexistence of diverse cell populations within a given tissue, with potential population cross-talk effects. Our findings suggest that in KEN mutations occur in a subset of epidermal precursors. Differences in the spectrum found in mosaic versus germline mutations could also contribute to the distinct phenotype. For example, p.G13R is the most common HRAS mutation in KEN whereas p.G12S is characteristic of CS. Differences in the mutational spectrum may, at least in part, be due to the strength of the biological effects of the amino acid substitution and the associated potential embryonic lethality. Similarly, the spectrum of KRAS mutations found in the germline in patients with developmental disorders differs from that of somatic changes in patients with cancer. 4 Interestingly, the HRAS p.G13R mutation occurs in tumours as well as in KEN, but it has not been described in the germline of CS patients, suggesting that although it is tolerated in the mosaic state, it may be lethal in the germline. The KRAS p.G12D mutationdthe most frequent somatic KRAS substitution found in cancerdhas been described in the mosaic Continued state in a 6-month-old infant with a KEN and a rhabdomyosarcoma 18 and is reported here in one KEN. This amino acid substitution has not been described in the germline, in agreement with the fact that its constitutive expression in the mouse is embryonic lethal. 19 Again, these data suggest that KRAS p.G12D is compatible with development and life only when it occurs in the mosaic state. Genetic mouse models allowing the controlled spatial and temporal activation of expression of RAS mutants in mice are potent tools to assess these hypotheses experimentally.
KEN occur in approximately 0.1% of live births 20 and about one third of them harbour HRAS mutations. By contrast, CS is very rare with only approximately 200 cases having been identified worldwide and a birth prevalence in the UK of approximately 1/500 000. 15 Based on these numbers, postzygotic HRAS mutations leading to mosaicism must be considerably more prevalent in patients than germline mutations. The common occurrence of mutations in oncogenes in KEN raises important questions regarding the mechanism of tumour formation and the risk of cancer in affected individuals. Secondary benign or malignant tumours have only seldom been reported in association with KEN, which are generally considered to be devoid of malignant potential. However, the risk of cancer associated with postzygotic mutations might depend on the extent of mosaicism, the tissues or cell types involved, and the specific mutation. HRAS, KRAS, and NRAS are involved in human tumours with a highly tissue-specific distribution that is not simply related to tissue expression patterns. Somatic HRAS mutations are common in tumours from the skin, cervix, upper aerodigestive tract, urinary tract, and salivary gland according to the COSMIC database.
In CS, HRAS germline mutations are associated with a predisposition to rhabdomyosarcoma, neuroblastoma, and urothelial carcinoma. 21 An association between KEN and noncutaneous malignancies of various organs has been reported, but the incidence and the individual risk for KEN patients is not known. 22 Although the occurrence of tumours in the patients with KEN in this study is not known, it is conceivable that patients with extensive KEN might have an increased risk of internal malignancies both during childhood and in adults. We have recently reported a subject with an extensive mosaicism for the HRAS p.G12S mutation: the patient had a systematised KEN and developed multiple urothelial carcinomas but did not show classical signs of CS. 23 This finding implies that oncogenic RAS mutations found in adult solid tumours can occur already during embryogenesis. In addition to the skin involvement, the occurrence of urothelial carcinoma and rhabdomyosarcoma may indicate some degree of phenotypic overlap between CS and KEN syndrome.
Mosaicism of oncogenic mutations can cause morphologically distinguishable lesions such as KEN in the skin, as we show here, but it may also occur in other tissues that are not amenable to simple tissue inspection, and contribute to cancer and nonneoplastic disorders at these sites. The frequency of mosaicism for Ras/MAPK pathway gene mutations in internal organs and tissues is unknown but it could be of clinical relevance.
Our findings suggest that a proportion of KEN can be considered as a RASopathy due to activation of the RAS/MAPK pathway by mutant RAS proteins. Because the term 'RASopathy' is defined by syndromes resulting from germline mutations, we suggest the term 'mosaic RASopathy' to describe KEN and KEN syndrome 18 23 as well as some rare cases of mosaic CS. 17 Additional syndromes may be added to this list in the future because the genetic basis of many mosaic disorders remains unknown.
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